inclusion criteria: * female and male patients competent to make a decision * proven and symptomatic sars-cov2 infection ≤ 5 days * patient age ≥ 18 years * provided written informed consent * chronic (≥ 1 month) acei/arb therapy for treatment of arterial hypertension, diabetes mellitus, heart failure or coronary artery disease * stable hemodynamic conditions allowing to stop or continue treatment with acei/arb (systolic blood pressure ≤180mmhg)

inclusion criteria: * female and male patients competent to make a decision * proven and symptomatic sars-cov2 infection ≤ 5 days * patient age ≥ 18 years * provided written informed consent * chronic (≥ 1 month) acei/arb therapy for treatment of arterial hypertension, diabetes mellitus, heart failure or coronary artery disease * stable hemodynamic conditions allowing to stop or continue treatment with acei/arb (systolic blood pressure ≤180mmhg)

inclusion criteria: - female and male patients competent to make a decision - proven and symptomatic sars-cov2 infection ≤ 5 days - patient age ≥ 18 years - provided written informed consent - chronic (≥ 1 month) acei/arb therapy for treatment of arterial hypertension, diabetes mellitus, heart failure or coronary artery disease - stable hemodynamic conditions allowing to stop or continue treatment with acei/arb (systolic blood pressure ≤180mmhg)

inclusion criteria: - female and male patients competent to make a decision - proven and symptomatic sars-cov2 infection ≤ 5 days - patient age ≥ 18 years - provided written informed consent - chronic (≥ 1 month) acei/arb therapy for treatment of arterial hypertension, diabetes mellitus, heart failure or coronary artery disease - stable hemodynamic conditions allowing to stop or continue treatment with acei/arb (systolic blood pressure ≤180mmhg)